2-amino-6,7-bis(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one | 139759-56-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-amino-6,7-bis(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 2-amino-6,7-bis(phenylmethoxy)-3,4-dihydro-2H-naphthalen-1-one
• CAS: 139759-56-1
• 化学式: C₂₄H₂₃NO₃
• 分子量: 373.452
• InChiKey: QITBLGISCWANMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6,7-bis(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one O-p-toluenesulfonyloxime 在 potassium ethoxide 作用下， 以 乙醇 、 苯 为溶剂， 反应 124.8h， 生成 2-amino-6,7-bis(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  对药物活性的构象影响。13.对先前提出的用于激活α-和β-肾上腺素受体的模型的修订。

  摘要：

  3-（3,4-二羟基苯基）的2-（3,4-二羟基苯基）吗啉3和4（2-DPM）的α1-，α2-，β1-和β2-肾上腺素能）-3-哌啶子醇5和6（3-DPP），以及反式-2-氨基-5,6-二羟基四氢萘-1-醇7和8和反式-2-氨基-6,7-二羟基四氢萘-1通过放射性配体结合测定和分离制剂的功能测试，对-ols 9和10（2-ADTNs）进行了体外评估，并与去甲肾上腺素（NE，1）和异丙肾上腺素（ISO，2）进行了比较。通过比较所检查化合物的立体结构及其生物药理特性，可以修改先前提出的直接激活α-和β-肾上腺素受体的分子模型。修改后的模型（AC）提供了有关肾上腺素能药物构象要求的信息，这与一些涉及构象受限的肾上腺素能受体激动剂的已发表研究的结果基本吻合。在模型B中，指α2受体和在模型C中，指β受体中的儿茶酚羟基的不同位置，证实了儿茶酚胺芳香环的旋转位置在与环糊精相互作用中的重要性。 α-和β-肾上腺素能受体。

  DOI：

  10.1021/jm00084a006

文献信息

• BETA-2 SELECTIVE ADRENERGIC RECEPTOR AGONISTS
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20200360304A1

  公开（公告）日：2020-11-19

  Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate β2AR with high selectivity over β1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective β-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.
• [EN] BETA-2 SELECTIVE ADRENERGIC RECEPTOR AGONISTS<br/>[FR] AGONISTES DE RÉCEPTEUR ADRÉNERGIQUE BÊTA-2 SÉLECTIF
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2019112913A1

  公开（公告）日：2019-06-13

  Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate β2AR with high selectivity over β1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective β-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.